Page 1449 - Williams Hematology ( PDFDrive )

1424 Part X: Malignant Myeloid Diseases Chapter 88: Acute Myelogenous Leukemia 1425

555. Shvidel L, Shaft D, Stark B, et al: Acute basophilic leukaemia: Eight unsuspected new 588. Wiernik PH, Banks PLC, Case DC Jr, et al: Cytarabine plus idarubicin or daunoru-
cases diagnosed by electron microscopy. Br J Haematol 120:774, 2003. bicin as induction and consolidation therapy for previously untreated adult patients
556. Yokohama A, Tsukamoto N, Hatsumi N, et al: Acute basophilic leukemia lacking with acute myeloid leukemia. Blood 79:313, 1992.
basophil-specific antigens: The importance of cytokine receptor expression in differ- 589. Flasshove M, Meusers P, Schutte J, et al: Long-term survival after induction therapy
ential diagnosis. Int J Hematol 75:309, 2002. with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia. Ann
557. Kubota M, Akiyama Y, Tabata Y, et al: Acute nonlymphocytic leukemia with basophilic Hematol 79:533, 2000.
differentiation and t(9;11)(p22;q23) in a child. Am J Hematol 31:133, 1989. 590. Hargrave RM, Davey MW, Davey RA, Kidman AD: Development of drug resistance in
558. Mezger J, Permanetter W, Gerhartz H, et al: Philadelphia chromosome-negative acute reduced idarubicin relative to other anthracyclines. Anticancer Drugs 6:432, 1995.
hematopoietic malignancy: Ultrastructural, cytochemical, and immunocytochemical 591. Feldman EJ: High-dose mitoxantrone in acute leukaemia: New York Medical College
evidence of mast cell and basophil differentiation. Leuk Res 14:169, 1990. experience. Eur J Cancer Care (Engl) 6:27, 1997.
559. Duchayne E, Demur C, Rubie H, et al: Diagnosis of acute basophilic leukemia. Leuk 592. Fernandez HF, Sun Z, Yao X, et al: Anthracycline dose intensification in acute myeloid
Lymphoma 32:269, 1999. leukemia. N Engl J Med 361:1249, 2009.
560. Petersen LC, Parkin JL, Arthur DC, Brunning RD: Acute basophilic leukemia. A 593. Lowenberg B, Ossenkoppele GJ, van Putten W, et al: High-dose daunorubicin in older
clinical, morphologic, and cytogenetic study of eight cases. Am J Clin Pathol 96:160, patients with acute myeloid leukemia. N Engl J Med 361:1235, 2009.
1991. 594. Kern W, Estey EH: High-dose cytosine arabinoside in the treatment of acute myeloid
561. Kubonishi I, Fijishita M, Niiya K, et al: Basophilic differentiation in acute promyelo- leukemia: Review of three randomized trials. Cancer 107:116, 2006.
cytic leukaemia. Nippon Ketsueki Gakkai Zasshi 48:1390, 1985. 595. Gardin C, Chevret S, Pautas C, et al: Superior long-term outcome with idarubicin
562. Pardanani AD, Morice WG, Hoyer JD, Tefferi A: Chronic basophilic leukemia: A dis- compared with high-dose daunorubicin in patients with acute myeloid leukemia age
tinct clinico-pathologic entity. Eur J Haematol 71:18, 2003. 50 years and older. J Clin Oncol 31:321, 2012.
563. Travis WD, Li C-Y, Hoaglan HC, et al: Mast cell leukemia. Report of a case and review 596. Ohtake S, Miyawaki S, Fujita H, et al: Randomized study of induction therapy com-
of the literature. Mayo Clin Proc 61:957, 1986. paring standard-dose idarubicin with high-dose daunorubicin in adult patients with
564. Beghini A, Cairoli R, Morra E, Larizza L: In vivo differentiation of mast cells from previously untreated acute myeloid leukemia: The JALSG AML201 study. Blood
acute myeloid leukemia blasts carrying a novel activating ligand-independent c-Kit 117:358, 2011.
mutation. Blood Cells Mol Dis 24:262, 1998. 597. NCCN Guidelines Version 2.2014 Acute Myeloid Leukemia. http://www.nccn.org/
565. Sperr WR, Horny HP, Lechner K, Valent P: Clinical and biological diversity of professionals/physician_gls/f_guidelines.asp. Last accessed July 2015.
leukemias occurring in patients with mastocytosis. Leuk Lymphoma 37:473, 2000. 598. Woodlock TJ, Lifton R, DiSalle M: Coincident acute myelogenous leukemia and
566. Fukuda T, Kakihara T, Kamishima T, et al: Leukemic cell membrane from acute ischemic heart disease: Use of the cardioprotectant dexrazoxane during induction
myelogenous leukemias with massive mast cell infiltration has a mast celldifferen- chemotherapy. Am J Hematol 59:246, 1998.
tiation activity under culture condition containing interleukin 3. Leuk Res 18:749, 599. Kern W, Estey EH: High-dose cytosine arabinoside in the treatment of acute myeloid
1994. leukemia: Review of three randomized trials. Cancer 107:116, 2006.
567. Valent P, Sperr WR, Samorapoompichit P, et al: Myelomastocytic overlap syndromes: 600. Lowenberg B, Pabst T, Vellenga E, et al: Cytarabine dose for acute myeloid leukemia.
Biology, criteria, and relationship to mastocytosis. Leuk Res 25:595, 2001. N Engl J Med 264:1027, 2011.
568. Levine PH, Weintraub LR: Pseudoleukemia during recovery from dapsone-induced 601. Burnett AK, Russell NH, Hills RK, et al: Optimization of chemotherapy for younger
agranulocytosis. Ann Intern Med 68:1060, 1968. patients with acute myeloid leukemia: Results of the medial research council AML15
569. Sanal SM, Campbell EW, Bowdler AJ, Brat PJ: Pseudoleukemia. Postgrad Med 65:143, trial. J Clin Oncol 31:3360, 2013.
1979. 602. Willemze R, Suciu S, Meloni G, et al: High-dose cytarabine in induction treatment
570. Dreskin SC, Iberti TJ, Watson-Williams EJ: Pseudoleukemia due to infection. J Med improves the outcome of adult patients younger than age 46 years with acute myeloid
14:147, 1983. leukemia: Results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol 32:219, 2013.
571. Lanham GR, Dahl GV, Billings FT, Stass SA: Pseudomonas aeruginosa infection with 603. Stein AS, O’Donnell MR, Slovak ML, et al: High-dose cytosine arabinoside and daunoru-
marrow suppression simulating acute promyelocytic leukemia. Am J Clin Pathol bicin induction therapy for adult patients with de novo non M3 acute myelogenous leuke-
80:404, 1983. mia: Impact of cytogenetics on achieving a complete remission. Leukemia 14:1191, 2000.
572. Orchard PJ, Moffet HL, Hafez R, Sondel PM: Pseudomonas sepsis simulating acute 604. Mehta J, Powles R, Treleaven J, et al: The impact of karyotype on remission rates in adult
promyelocytic leukemia. Pediatr Infect Dis J 7:66, 1988. patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based
573. Reykdal S, Sham R, Phatak P, Kouides P: Pseudoleukemia following the use of G-CSF. induction chemotherapy. Leuk Lymphoma 34:553, 1999.
Am J Hematol 49:258, 1995. 605. Archimbaud E, Thomas X, Leblond V, et al: Timed sequential chemotherapy for pre-
574. Innes DJ, Hess CE, Bertholf MF, Wade P: Promyelocyte morphology: Differentiation viously treated patients with acute myeloid leukemia: Long-term follow-up of the
of acute promyelocytic leukemia from benign myeloid proliferations. Am J Clin Pathol etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 13:11, 1995.
88:725, 1987. 606. Archimbaud E, Leblond V, Fenaux P, et al: Timed sequential chemotherapy for
575. Ahmed MA: Promyelocytic leukaemoid reaction: An atypical presentation of myco- advanced acute myeloid leukemia. Hematol Cell Ther 38:161, 1996.
bacterial infection. Acta Haematol 85:143, 1991. 607. Thomas X, Dombret H: Timed-sequential chemotherapy as induction and/or consol-
576. Sekeres MA, Elson P, Kalaycio ME: Time from diagnosis to treatment initiation idation regimen for younger adults with acute myelogenous leukemia. Hematology
predicts survival in younger, but not older, acute myeloid leukemia patients. Blood 12:15, 2007.
113:28, 2009. 608. Bolanos-Meade J, Karp JE, Guo C, et al: Timed sequential therapy of acute myel-
577. Rodriguez CP, Baz R, Jawde RA, et al: Impact of socioeconomic status and distance ogenous leukemia in adults: A phase II study of retinoids in combination with the
from treatment center on survival in patients receiving remission induction therapy sequential administration of cytosine arabinoside, idarubicin and etoposide. Leuk Res
for newly diagnosed acute myeloid leukemia. Leuk Res 32:413, 2008. 27:313, 2003.
578. Wedding U, Röhrig B, Klippstein A, et al: Impairment in functional status and sur- 609. Kell WJ, Burnett AK, Chopra R, et al: A feasibility study of simultaneous adminis-
vival in patients with acute myeloid leukaemia. J Cancer Res Clin Oncol 132:665, tration of gemtuzumab ozogamicin with intensive chemotherapy in induction and
2006. consolidation in younger patients with acute myeloid leukemia. Blood 102:4277, 2003.
579. Karthaus M, Doellmann T, Klimasch T, et al: Central venous catheter infections in 610. Borthakur G, Kantarjian H, Wang X, et al: Treatment of core-binding-factor in acute
patients with acute leukemia. Chemotherapy 48:154, 2002. myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimu-
580. Hummel M, Duchheidt D, Reiter S, et al: Successful treatment of hyperuricemia with lating factor results in improved event-free survival. Cancer 113:3181, 2008.
low doses of recombinant urate oxidase in four patients with hematologic malignancy 611. Holowiecki J, Grosicki S, Robak T, et al: Addition of cladribine to daunomycin and
and tumor lysis syndrome. Leukemia 17:2542, 2003. cytarabine increases remission rate after a single course of induction treatment in
581. Lo Coco F, Pelicci PG, D’Adamo F, et al: Polyclonal hematopoietic reconstitution in acute myeloid leukemia. Multicenter phase III study. Leukemia 18:989, 2004.
leukemia patients in remission after suppression of specific gene rearrangements. 612. Estey EH, Thall PF, Cortes JE, et al: Comparison of idarubicin + ara-C, and topotecan
Blood 82:606, 1993. + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed
582. Lichtman MA: The stem cell in the pathogenesis and treatment of myelogenous leuke- acute myeloid leukemia, refractory anemia with excess blasts in transformation, or
mia. Leukemia 15:1489, 2001. refractory anemia with excess blasts. Blood 98:3575, 2001.
583. Sanz MA, Jarque I, Martin G, et al: Acute promyelocytic leukemia. Cancer 6:7, 1988. 613. Holowiecki J, Grosicki S, Giebel S et al: Cladribine, but not fludarabine, added to dauno-
584. Hiddemann W, Spiekermann K, Buske C, et al: Towards a pathogenesis-oriented ther- rubicin and cytarabine during induction prolongs survival of patients with acute mye-
apy of acute myeloid leukemia. Crit Rev Oncol Hematol 56:235, 2005. loid leukemia: A multicenter, randomized phase II study. J Clin Oncol 30:2441, 2012.
585. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the Interna- 614. Attar EC, Johnson JL, Amrein PC, et al: Bortezomib added to daunorubicin and cyta-
tional Working Group for Diagnosis, Standards for Therapeutic Trials in Acute Mye- rabine during induction therapy and to intermediate-dose cytarabine for consolida-
loid Leukemia. J Clin Oncol 21:4642, 2003. tion in patients with previously untreated acute myeloid leukemia age 60 to 75 years:
586. Fey M, Dreyling M: ESMO Guidelines Working Group: Acute myeloblastic leuke- CALGB (Alliance) study 10502. J Clin Oncol 31:923, 2012,
mia in adult patients: ESMO clinical recommendations for diagnosis, treatment and 615. Giles F: Gemtuzumab ozogamicin: A component of induction therapy in AML? Leuk
follow-up. Ann Oncol 19 Suppl 2:ii58, 2008. Res 29:1, 2005.
587. O’Donnell MR, Abboud CN, Altman J, et al: Acute myeloid leukemia. J Natl Compr- 616. Tallman M: Existing and emerging therapeutic options for the treatment of acute
Canc Netw 10:984, 1012, 2012. myeloid leukemia. Clin Adv Hematol Oncol 6:3, 2008.

Kaushansky_chapter 88_p1373-1436.indd 1424 9/21/15 11:02 AM